General Partner of Polaris Venture Partners

Amir Nashat is a general partner in our Boston office. Amir joined Polaris in April 2002 and focuses on investments in the life sciences.

Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir’s doctoral research focused on information flow through neurons, neural implants, and neural tissue engineering. During his time at M.I.T., Amir completed an internship in the London office of Goldman, Sachs & Company, where he worked on interest rate derivative products.

Amir currently represents Polaris as a Director of Athenix Corporation, eNOS Pharmaceuticals, Hydra Biosciences, Promedior Pharmaceuticals, Pervasis Therapeutics, Inc., where he was founding president, T2 Biosystems and WaveRx. Additionally, Amir is a Board Observer to GI Dynamics, and supports Polaris' investment in Advion.

Amir currently serves on the Board of the New England Venture Capital Association, on the Advisory Board of the Simmons School of Management Entrepreneurship Initiative, and is a Catalyst for the Deshpande Center for Technological Innovation at M.I.T. Prior to obtaining his Ph.D. at MIT, Amir earned both his M.S. and B.S. in Materials Science and Mechanical Engineering at the University of California, Berkeley.